Results 21 to 30 of about 11,283,677 (180)

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood, 2021
Background: Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is approved for the treatment of pts with relapsed/refractory LBCL with ≥ 2 prior systemic therapies.
C. Jacobson, F. Locke, A. Ghobadi, D. Miklos, L. Lekakis, O. Oluwole, Yi Lin, B. Hill, J. Timmerman, A. Deol, P. Reagan, P. Stiff, I. Flinn, U. Farooq, A. Goy, J. Muñoz, T. Siddiqi, R. Shen, A. Bot, Jinghui Dong, Kanwarjit Singh, C. Spooner, Roshan Karalliyadda, Jenny J. Kim, Yan Zheng, S. Neelapu   +25 more
semanticscholar   +1 more source

Imported ornaments of a Late Antiquity community in Christian Ethiopia [PDF]

, 2022
Several thousand glass beads excavated in the Maryam Anza (Tigray, Ethiopia) cemetery over three seasons between 2014 and 2016 tell the story of the direct or indirect long-distance contacts of the people buried there.
Phillips, Jacke, Then-Obłuska, Joanna, Tucker, Katie   +2 more
core   +2 more sources

In Search of the Nubian Master-Builders: An Architectural Drawing from the Faras Cathedral. Appendix: Prayer of a Young Woman [PDF]

, 2016
A glance at a makeshift drawing from the cathedral in Faras suggests that it may depict the ground plan of a church. Nevertheless, the naive appearance of the sketch and an almost complete lack of sufficient parallels from either Nubia or the Eastern ...
Piotr Makowski, Vincent van Gerven Oei
core   +1 more source

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Haematologica, 2022
Here we present the 3-year results of ZUMA-4, a phase I/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in pediatric/adolescent patients with relapsed/refractory B-
A. Wayne, V. Huynh, N. Hijiya, R. Rouce, P. Brown, J. Krueger, C. Kitko, Edward Dela Ziga, M. Hermiston, M. Richards, A. Baruchel, P. Schuberth, J. Rossi, Lang Zhou, L. Goyal, R. Jain, R. Vezan, B. K. Masouleh, Daniel W. Lee   +18 more
semanticscholar   +1 more source

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Blood, 2023
Introduction Brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 CAR T-cell therapy, is approved in the US for the treatment of relapsed/refractory (r/r) mantle cell lymphoma (MCL) and in Europe for r/r MCL after ≥2 prior lines of therapies,
Nora Liebers, H. Finel, Dominic Edelmann, G. Kobbe, Ben-Niklas Bärmann, Y. Serroukh, D. Blaise, D. Beelen, C. Solano, M. Itäla-remes, A. Broers, G. Choi, N. Kroeger, J. Byrne, J. Tudesq, Ana Nunes, R. Siddiqi, Elande Baro, Dan Zheng, I. Kloos, P. Dreger, Anna Sureda Balari, B. Glass, Sascha Dietrich   +23 more
semanticscholar   +1 more source

Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

Blood Cancer Discovery, 2023
Associations between axi-cel product features, apheresis attributes, pharmacokinetics, pharmacodynamics, and clinical outcomes were uncovered in ZUMA-7, the largest clinical trial for CAR T-cell therapy in second-line LBCL.
S. Filosto, S. Vardhanabhuti, M. Canales, X. Poiré, L. Lekakis, S. de Vos, C. Portell, Zixing Wang, C. To, M. Schupp, S. Poddar, T. Trinh, Carmen M Warren, Ethan A. Aguilar, J. Budka, Paul Cheng, J. Chou, Adrian Bot, Rhine R Shen, J. Westin   +19 more
semanticscholar   +1 more source

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Blood Advances, 2021
Key Points Propensity analysis confirmed substantially higher ORR and a 73% reduction in risk for death with axi-cel vs standard salvage regimens. This 2-year analysis indicates that axi-cel is associated with durable clinical benefit for patients with ...
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, P. Reagan, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, M. Crump, J. Kuruvilla, E. Van Den Neste, U. Farooq, L. Navale, Venita Depuy, Jenny J. Kim, C. Gisselbrecht   +18 more
semanticscholar   +1 more source

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Blood, 2020
Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma.
S. Neelapu, C. Jacobson, O. Oluwole, J. Muñoz, A. Deol, D. Miklos, N. Bartlett, I. Braunschweig, Yi-zhou Jiang, Jenny J. Kim, Lianqing Zheng, J. Rossi, F. Locke   +12 more
semanticscholar   +1 more source

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY

HemaSphere, 2022
Background: Background: Despite the success of axi-cel, ≈60% of patients have no response or relapse within ~2 y after treatment (Jacobson C, et al. ASH 2021. #1764), highlighting the need for more therapeutic strategies.
P. Strati, L. Leslie, P. Shiraz, E. Budde, O. Oluwole, M. Ulrickson, A. Ramakrishnan, J. Sun, R. Shen, J. Kanska, P. McCroskery, J. Dong, M. Schupp, H. Xu, K. Patel   +14 more
semanticscholar   +1 more source

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood, 2021
Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of R/R large B-cell lymphoma and follicular lymphoma (FL), both after ≥2 lines of systemic therapy.
S. Neelapu, J. Chavez, A. Sehgal, N. Epperla, M. Ulrickson, E. Bachy, Pashna N. Munshi, C. Casulo, D. Maloney, S. de Vos, R. Reshef, L. Leslie, O. Oluwole, I. Yakoub-Agha, R. Khanal, J. Rosenblatt, M. Sherman, Jinghui Dong, A. Giovanetti, Yin Yang, C. Lui, Z. Bashir, A. S. Jung, C. Jacobson   +23 more
semanticscholar   +1 more source